

Application No.: 10/047608

Docket No.: ALXN-P01-059

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-26 (Cancelled).

27. (Currently Amended) A method of prophylaxis against a myocardial infarction in a patient undergoing cardiopulmonary bypass surgery, said method comprising the steps of:

- a) administering an anti-inflammatory agent as a bolus to said patient prior to or simultaneously with the start of said surgery, and
- b) administering additional said anti-inflammatory agent subsequent to administering said bolus.

28. (Previously Presented) The method of claim 27 wherein said surgery is coronary artery bypass graft surgery or heart transplant surgery.

29. (Previously Presented) The method of claim 27 wherein said anti-inflammatory agent is a complement inhibitor.

30. (Previously Presented) The method of claim 29 wherein said complement inhibitor is selected from the group consisting of a) an antibody directed against complement component C1, C2, C3, C4, C5, C6, C7, C8 or C9, b) an antibody against Factor D, Factor B, Factor P, MBL, MASP-1, or MASP-2, and c) CR1, LEX-CR1, MCP, DAF, CD59, Factor H, cobra venom factor, Fut-175, y bind protein, complestatin, or K76COOH.

31. (Previously Presented) The method of claim 29 wherein the complement inhibitor is an antibody against C5 which prevents the conversion of C5 into C5a and C5b.

32. (Previously Presented) The method of claim 31 wherein said antibody is a polypeptide comprising an amino acid sequence of amino acids 1 through 248 selected from the group

Application No.: 10/047608

Docket No.: ALXN-P01-059

consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

33. (Cancelled).

34. (Previously Presented) The method of claim 27 wherein step (b) comprises an infusion administration of said anti-inflammatory agent.

35-41. (Cancelled).